|
1
|
He D, Wang J, Zhang C, Shan B, Deng X, Li
B, Zhou Y, Chen W, Hong J, Gao Y, et al: Down-regulation of
miR-675-5p contributes to tumor progression and development by
targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol
Cancer. 14:732015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu
X, Yuan J and Li M: MiR-503 targets PI3K p85 and IKK-β and
suppresses progression of non-small cell lung cancer. Int J Cancer.
135:1531–1542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang B, Liu T, Wu T, Wang Z, Rao Z and
Gao J: microRNA-137 functions as a tumor suppressor in human
non-small cell lung cancer by targeting SLC22A18. Int J Biol
Macromol. 74:111–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crinò L, Weder W, van Meerbeeck J and
Felip E: ESMO Guidelines Working Group: Early stage and locally
advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 21(Suppl 5): v103–v115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu X, Wei F, Yu J, Zhao H, Jia L, Ye Y, Du
R, Ren X and Li H: Matrix metalloproteinase 13: A potential
intermediate between low expression of microRNA-125b and increasing
metastatic potential of non-small cell lung cancer. Cancer Genet.
208:76–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu X, Gao G, Chu K, Yang X, Ren S, Li Y,
Wu H, Huang Y and Zhou C: Inhibition of RAC1-GEF DOCK3 by
miR-512-3p contributes to suppression of metastasis in non-small
cell lung cancer. Int J Biochem Cell Biol. 61:103–114. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engels BM and Hutvagner G: Principles and
effects of microRNA-mediated post-transcriptional gene regulation.
Oncogene. 25:6163–6169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Rooij E, Purcell AL and Levin AA:
Developing microRNA therapeutics. Circ Res. 110:496–507. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen C, Zhao Z, Liu Y and Mu D:
microRNA-99a is downregulated and promotes proliferation, migration
and invasion in non-small cell lung cancer A549 and H1299 cells.
Oncol Lett. 9:1128–1134. 2015.PubMed/NCBI
|
|
13
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Broderick JA and Zamore PD: MicroRNA
therapeutics. Gene Ther. 18:1104–1110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun YC, Wang J, Guo CC, Sai K, Wang J,
Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: MiR-181b
sensitizes glioma cells to teniposide by targeting MDM2. BMC
Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang T, Thakur A, Chen T, Yang L, Lei G,
Liang Y, Zhang S, Ren H and Chen M: MicroRNA-15a induces cell
apoptosis and inhibits metastasis by targeting BCL2L2 in non-small
cell lung cancer. Tumour Biol. 36:4357–4365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang J, Liu H, Wang H and Sun Y:
Down-regulation of microRNA-181b is a potential prognostic marker
of non-small cell lung cancer. Pathol Res Pract. 209:490–494. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Visone R, Veronese A, Balatti V and Croce
CM: MiR-181b: New perspective to evaluate disease progression in
chronic lymphocytic leukemia. Oncotarget. 3:195–202. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi ZM, Wang XF, Qian X, Tao T, Wang L,
Chen QD, Wang XR, Cao L, Wang YY, Zhang JX, et al: MiRNA-181b
suppresses IGF-1R and functions as a tumor suppressor gene in
gliomas. RNA. 19:552–560. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang RJ, Zheng YH, Wang P and Zhang JZ:
Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in
non-small cell lung cancer. Int J Clin Exp Pathol. 8:765–771.
2015.PubMed/NCBI
|
|
25
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mountain CF and Dresler CM: Regional lymph
node classification for lung cancer staging. Chest. 111:1718–1723.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang R, Chen XF and Shu YQ: Prediction of
non-small cell lung cancer metastasis-associated microRNAs using
bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
|
|
28
|
Jiang J, Zheng X, Xu X, Zhou Q, Yan H,
Zhang X, Lu B, Wu C and Ju J: Prognostic significance of miR-181b
and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin
or Doxifluridine/Oxaliplatin. PLoS One. 6:e232712011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li D, Jian W, Wei C, Song H, Gu Y, Luo Y
and Fang L: Down-regulation of miR-181b promotes apoptosis by
targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol.
7:7672–7680. 2014.PubMed/NCBI
|
|
30
|
Zhi F, Wang Q, Deng D, Shao N, Wang R, Xue
L, Wang S, Xia X and Yang Y: MiR-181b-5p downregulates NOVA1 to
suppress proliferation, migration and invasion and promote
apoptosis in astrocytoma. PLoS One. 9:e1091242014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu F, Zhang J, Ji M, Li P, Du Y, Wang H,
Zang S, Ma D, Sun X and Ji C: miR-181b increases drug sensitivity
in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J
Oncol. 45:383–392. 2014.PubMed/NCBI
|
|
32
|
Xia Y and Gao Y: MicroRNA-181b promotes
ovarian cancer cell growth and invasion by targeting LATS2. Biochem
Biophys Res Commun. 447:446–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu
P, Wei J, Jiang K and Miao Y: miRNA-181b increases the sensitivity
of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro
and in nude mice by targeting BCL-2. Oncol Rep. 29:1769–1776.
2013.PubMed/NCBI
|
|
34
|
Ferrari S, Finelli P, Rocchi M and Bianchi
ME: The active gene that encodes human high mobility group 1
protein (HMG1) contains introns and maps to chromosome 13.
Genomics. 35:367–371. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yao S, Zhao T and Jin H: Expression of
MicroRNA-325-3p and its potential functions by targeting HMGB1 in
non-small cell lung cancer. Biomed Pharmacother. 70:72–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen X, Hong L, Sun H, Shi M and Song Y:
The expression of high-mobility group protein box 1 correlates with
the progression of non-small cell lung cancer. Oncol Rep.
22:535–539. 2009.PubMed/NCBI
|
|
37
|
Sun KK, Ji C, Li X, Zhang L, Deng J, Zhong
N and Wu XY: Overexpression of high mobility group protein B1
correlates with the proliferation and metastasis of lung
adenocarcinoma cells. Mol Med Rep. 7:1678–1682. 2013.PubMed/NCBI
|
